How to Start Statins – A Quick Clinical Guide
Introduction
Statins remain the cornerstone of lipid-lowering therapy and cardiovascular risk reduction. By inhibiting HMG-CoA reductase, they significantly reduce LDL cholesterol and prevent atherosclerotic cardiovascular disease (ASCVD). Correct patient selection, appropriate intensity, and proper follow-up are essential for optimal outcomes.
---
What Are Statins?
Statins are lipid-lowering agents that:
Inhibit HMG-CoA reductase
Reduce LDL cholesterol
Stabilize atherosclerotic plaques
Decrease risk of MI, stroke, and cardiovascular death
---
When to Start Statins (Key Indications)
1. Established ASCVD
Previous myocardial infarction
Ischemic stroke
Peripheral arterial disease
→ Start high-intensity statin
2. LDL ≥190 mg/dL
Suggests familial hypercholesterolemia
→ Start high-intensity statin
3. Diabetes Mellitus (Age 40–75)
LDL ≥70 mg/dL
→ Start moderate-intensity statin
→ Consider high-intensity if multiple risk factors
4. High 10-Year ASCVD Risk
Age 40–75 years
LDL ≥70 mg/dL
→ Start statin based on risk calculation
≥20% → High-intensity
7.5–19.9% → Moderate-intensity
---
Statin Intensity Classification
High-Intensity Statins (↓ LDL ≥50%)
Atorvastatin 40–80 mg
Rosuvastatin 20–40 mg
Moderate-Intensity Statins (↓ LDL 30–49%)
Atorvastatin 10–20 mg
Rosuvastatin 5–10 mg
Simvastatin 20–40 mg
---
Baseline Evaluation Before Starting
Lipid profile
ALT (liver enzymes)
Creatine kinase (CK) → if risk of myopathy
---
Important Precautions
Avoid in active liver disease
Contraindicated in pregnancy
Monitor for:
Myalgia
Muscle weakness
Rare rhabdomyolysis
---
Follow-Up Strategy
Repeat lipid profile after 4–12 weeks
Assess adherence and response
Target:
≥50% LDL reduction in high-risk patients
Adjust dose or escalate therapy if needed
---
Practical Clinical Tips
Start early in high-risk patients—delay increases events
Don’t overcheck CK unless symptomatic
Mild transaminase elevation is not a contraindication
Combine lifestyle + statin for best outcomes
---
Conclusion
Statin initiation should be systematic and risk-based. Identifying the right patient, choosing appropriate intensity, and ensuring regular follow-up can dramatically reduce cardiovascular morbidity and mortality.

Comments
Post a Comment
Drop your thoughts here, we would love to hear from you